Invivyd, Inc. (IVVD) stock
IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3048% below fair value
$0.51−0.03 (-4.67%)
Close on Nov 17, 2026Market cap $151.09MP/E –Yield –
Invivyd r&d expenses
Research and development expenses are spending on new products and technology.
Invivyd's R&D Expenses for the twelve months ending Jun 30, 2026 was $78.19M, down 18.5% year over year. For fiscal 2025 it was $38.31M, down 72.1% from the year before. The highest annual figure on record is $182.89M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.31M | -72.1% |
| FY2024 | Dec 31, 2024 | $137.25M | -13.5% |
| FY2023 | Dec 31, 2023 | $158.66M | -11.5% |
| FY2022 | Dec 31, 2022 | $179.21M | -2.0% |
| FY2021 | Dec 31, 2021 | $182.89M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $29.37M | +206.8% |
| Q1 FY2026 | Mar 31, 2026 | $30.73M | +188.8% |
| Q4 FY2025 | Dec 31, 2025 | $10.05M | -43.9% |
| Q3 FY2025 | Sep 30, 2025 | $8.05M | -86.1% |
| Q2 FY2025 | Jun 30, 2025 | $9.57M | -68.4% |
| Q1 FY2025 | Mar 31, 2025 | $10.64M | -65.9% |
| Q4 FY2024 | Dec 31, 2024 | $17.91M | -71.2% |
| Q3 FY2024 | Sep 30, 2024 | $57.85M | +126.2% |
| Q2 FY2024 | Jun 30, 2024 | $30.33M | -30.5% |
| Q1 FY2024 | Mar 31, 2024 | $31.16M | +14.6% |
| Q4 FY2023 | Dec 31, 2023 | $62.27M | +212.6% |
| Q3 FY2023 | Sep 30, 2023 | $25.57M | -15.1% |
| Q2 FY2023 | Jun 30, 2023 | $43.62M | +17.5% |
| Q1 FY2023 | Mar 31, 2023 | $27.20M | -70.4% |
| Q4 FY2022 | Dec 31, 2022 | $19.92M | -70.9% |
| Q3 FY2022 | Sep 30, 2022 | $30.13M | -33.6% |
| Q2 FY2022 | Jun 30, 2022 | $37.13M | +5.9% |
| Q1 FY2022 | Mar 31, 2022 | $92.04M | +170.4% |
| Q4 FY2021 | Dec 31, 2021 | $68.43M | +843.7% |
| Q3 FY2021 | Sep 30, 2021 | $45.37M | – |
| Q2 FY2021 | Jun 30, 2021 | $35.07M | – |
| Q1 FY2021 | Mar 31, 2021 | $34.03M | – |
| Q3 FY2020 | Sep 30, 2020 | $7.25M | – |
See a number that looks wrong?